Publication | Closed Access

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

UrologyGenitourinary CancerMedicineMetastatic Renal CarcinomaAntisense Oligonucleotide Mg98Cancer TreatmentOncologyRadiation OncologyCancer ResearchDna Methyltransferase 1